Brolucizumab outperforms aflibercept in fluid resolution

Findings from a pair of phase 3 trials suggest that the new VEGF inhibitor brolucizumab is more effective than aflibercept at resolving retinal fluid in patients with wet AMD.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553